4 Biotech Stocks That More Than Doubled In 2016

(Click on image to enlarge)

 Exelixis, Inc. (EXEL - Free Report) : South San Francisco, CA-based Exelixis is focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. The company has had a phenomenal run in 2016 outperforming the Zacks categorized Medical/Biomedical Genetics industry by a huge margin. Exelixis’ shares are up 189.3% YTD compared to the industry decline of 25.4%.

Exelixis’ portfolio includes two products derived from cabozantinib -- Cabometyx tablets (treatment of advanced kidney cancer) and Cometriq capsules (treatment of certain forms of thyroid cancer). Another product, Cotellic, derived from cobimetinib, is marketed under a collaboration with Roche (for use in combination with Zelboraf to treat advanced melanoma).

Recently approved Cabometyx had a strong full quarter driven by METEOR data and commercial execution. The product already has a 19% share in the second line metastatic kidney cancer market and 35% of the third-line segment. A major catalyst for Exelixis would be approval for the first-line indication -- the company has already presented pretty impressive results in October for the first-line patient population and is looking to seek approval for this indication. The first-line patient population represents huge commercial potential.

Exelixis is evaluating Cabometyx in several studies for different types of cancer and has other candidates in its pipeline including CS-3150 (partnered with Daiichi Sankyo). The company has made significant progress towards its goal of becoming a profitable, fully integrated, commercial company. 

(Click on image to enlarge)

TESARO, Inc. (TSRO - Free Report) : Waltham, MA-based TESARO is another cancer-focused company that saw its shares soaring in 2016 on impressive data. TESARO’s shares shot up in Jun 2016 when the company presented impressive data on its PARP inhibitor, niraparib. YTD, TESARO’s shares are up a whopping 161.5%. The company is currently seeking FDA approval for niraparib for a certain type of ovarian cancer -- the agency has granted the drug priority review with a response expected by Jun 30, 2017. Importantly, the FDA does not expect to hold an advisory committee meeting for the candidate. PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology and represent immense commercial potential. 

View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.